FDA
-
-
-
-
-
-
-
Bayer receives FDA approval for lowest-dose MRI contrast agent
-
-
-
-
-
-
-
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
-
-
-
-
-
-
-
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
-
-
-
-
-
-
-
Bayer Accelerates Pharma Growth on High-Value Portfolio
-
-
-
-
-
-
-
FDA approves Bayer's HYRNUO for HER2-mutated lung cancer treatment
-
-
-
-
-
-
-
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
-
-
330,738 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

